Page last updated: 2024-11-08

adenosine 5'-o-(3-thiotriphosphate)

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

adenosine 5'-O-(3-thiotriphosphate): RN given refers to cpd with unspecified locant for thio group; see also records for 1-thio & 2-thio-isomers [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

adenosine 5'-[gamma-thio]triphosphate : A nucleoside triphosphate analogue that is ATP in which one of the oxygens attached to 3-phosphate group is replaced by sulfur. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID440317
CHEMBL ID131890
CHEBI ID27575
SCHEMBL ID77440
SCHEMBL ID20164791
MeSH IDM0078832

Synonyms (49)

Synonym
117750-47-7
alpha-thioadenosine triphosphate
adenosine, 5'-p''-ester with thiotriphosphoric acid ((ho)2p(o)op(o)(oh)op(35s)(oh)2)
alpha-thio-atp
adenosine 5'-thiotriphosphate
adenosine 5'-(trihydrogen diphosphate), p'-anhydride with phosphorothioic acid
gamma-thio-atp
(gamma-s)atp
adenosine 5'-(trihydrogen diphosphate), p'-anhydride with phosphorothioic acid (9ci)
adenosine, 5'-o-[[[[(dihydroxyphosphinothioyl)oxy]hydroxyphosphinyl]oxy]hydroxyphosphinyl]-
adenosine 5'-[gamma-s]triphosphate
adenosine 5'-(trihydrogen diphosphate), monoanhydride with phosphorothioic acid
adenosine 5'-(gamma-thiotriphosphate)
adenosine 5'-(gamma-s)triphosphate
adenosine 5'-o-(gamma-thiotriphosphate)
adenosine 5'-(3-thiotriphosphate)
35094-46-3
[[[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methoxy-hydroxy-phosphoryl]oxy-hydroxy-phosphoryl]oxy-sulfanyl-phosphinic acid
adenosine 5'-(.gamma.-s)triphosphate
atp.gamma.s
adenosine 5'-[gamma-thio]triphosphate
adenosine 5'-o-(3-thiotriphosphate)
CHEBI:27575 ,
atp-gammas
adenosine 5'-(3-thio)triphosphate
5'-o-(hydroxy{[hydroxy(thiophosphonooxy)phosphoryl]oxy}phosphoryl)adenosine
adenosine-5'-(3-thiotriphosphate)
adenosine 5'-o-thiotriphosphate
phosphothiophosphoric acid-adenylate ester
adenosine 5-o-(3-thiotriphophate)
adenosine 5'-(gamma-thio)triphosphate
atp-gamma-s
adenosine-5'-diphosphate monothiophosphate
gamma thio atp
1XXH
1NJF
DB02930
1W1W
CHEMBL131890 ,
bdbm50118217
adenosine-5''-diphosphate monothiophosphate
[[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] dihydroxyphosphinothioyl hydrogen phosphate
[[[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-sulfanylphosphinic acid
SCHEMBL77440
adenosine-5'-o-(1-thiotriphosphate), sp-isomer sodium salt
5'-o-[(s)-hydroxy{[(s)-hydroxy(thiophosphonooxy)phosphoryl]oxy}phosphoryl]adenosine
adenosine 5 inverted exclamation marka-(3-thiotriphosphate)
SCHEMBL20164791
DTXSID301138619

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" ATP dose-response experiments, taken together with the effect of cAMP with and without ATP, suggest that phosphorylation is necessary, but not sufficient, for activation."( Regulation of CFTR Cl- conductance in secretion by cellular energy levels.
Bell, CL; Quinton, PM, 1993
)
0.29
" Construction of dose-response curves to ATP, ATP gamma S and UTP in the presence and absence of additional agonists showed that responses to ATP gamma S and UTP were not additive, nor were those to UTP and ATP."( Evidence for a nucleotide receptor on adrenal medullary endothelial cells linked to phospholipase C and phospholipase D.
Boarder, MR; Purkiss, JR; Wilkinson, GF, 1993
)
0.29
" In slices from heterozygous mice the dose-response curve for both adenosine and ATP was shifted to the right."( Modulation of hippocampal glutamatergic transmission by ATP is dependent on adenosine a(1) receptors.
Diao, L; Dunwiddie, TV; Fredholm, BB; Illes, P; Johansson, B; Larson, GA; Masino, SA; Zahniser, NR, 2002
)
0.31
" Intriguingly, ATP had a biphasic effect on breast cancer cells-lower dosage inhibited but higher dosage promoted its migration."( Differential impact of adenosine nucleotides released by osteocytes on breast cancer growth and bone metastasis.
Ellies, LG; Gao, X; Jiang, JX; Riquelme, MA; Sun, LZ; Zhou, JZ, 2015
)
0.42
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
nucleoside triphosphate analogue
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (17)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, DNA polymerase III subunit gammaEscherichia coliKd1.03001.03001.03001.0300AID977611
Chain D, DNA polymerase III subunit gammaEscherichia coliKd0.78000.78001.89003.0000AID977611
Chain D, DNA polymerase III subunit gammaEscherichia coliKd0.78000.78001.89003.0000AID977611
Mu-type opioid receptorHomo sapiens (human)EC50 (µMol)1.30000.00000.32639.4000AID150172
Delta-type opioid receptorHomo sapiens (human)EC50 (µMol)1.30000.00000.43328.3000AID150172
Kappa-type opioid receptorHomo sapiens (human)EC50 (µMol)1.30000.00000.22448.9900AID150172
P2Y purinoceptor 2Homo sapiens (human)EC50 (µMol)1.72000.00560.682810.0000AID1372694; AID150321
P2X purinoceptor 1Rattus norvegicus (Norway rat)EC50 (µMol)2.30000.05402.761310.0000AID152476
P2Y purinoceptor 1Meleagris gallopavo (turkey)EC50 (µMol)1.30000.00251.70498.0000AID150470
P2X purinoceptor 2Rattus norvegicus (Norway rat)EC50 (µMol)1.50001.50001.50001.5000AID150144
P2X purinoceptor 1Homo sapiens (human)EC50 (µMol)2.30000.05402.462310.0000AID152476
P2X purinoceptor 4Rattus norvegicus (Norway rat)EC50 (µMol)2.30002.30006.566710.0000AID150166
P2X purinoceptor 5Rattus norvegicus (Norway rat)EC50 (µMol)0.60000.60002.05004.0000AID150170
P2X purinoceptor 6Rattus norvegicus (Norway rat)EC50 (µMol)1.30000.60000.95001.3000AID150172
P2X purinoceptor 3Homo sapiens (human)EC50 (µMol)0.69000.24002.80229.2000AID150151
P2Y purinoceptor 11Homo sapiens (human)EC50 (µMol)1.53160.06313.77049.0000AID150489; AID302984
P2Y purinoceptor 12Rattus norvegicus (Norway rat)EC50 (µMol)1.30000.00111.09044.0000AID150495
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (94)

Processvia Protein(s)Taxonomy
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMu-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
sensory perceptionMu-type opioid receptorHomo sapiens (human)
negative regulation of cell population proliferationMu-type opioid receptorHomo sapiens (human)
sensory perception of painMu-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
behavioral response to ethanolMu-type opioid receptorHomo sapiens (human)
positive regulation of neurogenesisMu-type opioid receptorHomo sapiens (human)
negative regulation of Wnt protein secretionMu-type opioid receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeMu-type opioid receptorHomo sapiens (human)
calcium ion transmembrane transportMu-type opioid receptorHomo sapiens (human)
cellular response to morphineMu-type opioid receptorHomo sapiens (human)
regulation of cellular response to stressMu-type opioid receptorHomo sapiens (human)
regulation of NMDA receptor activityMu-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayMu-type opioid receptorHomo sapiens (human)
immune responseDelta-type opioid receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerDelta-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
adult locomotory behaviorDelta-type opioid receptorHomo sapiens (human)
negative regulation of gene expressionDelta-type opioid receptorHomo sapiens (human)
negative regulation of protein-containing complex assemblyDelta-type opioid receptorHomo sapiens (human)
positive regulation of CREB transcription factor activityDelta-type opioid receptorHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationDelta-type opioid receptorHomo sapiens (human)
response to nicotineDelta-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
eating behaviorDelta-type opioid receptorHomo sapiens (human)
regulation of mitochondrial membrane potentialDelta-type opioid receptorHomo sapiens (human)
regulation of calcium ion transportDelta-type opioid receptorHomo sapiens (human)
cellular response to growth factor stimulusDelta-type opioid receptorHomo sapiens (human)
cellular response to hypoxiaDelta-type opioid receptorHomo sapiens (human)
cellular response to toxic substanceDelta-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayDelta-type opioid receptorHomo sapiens (human)
immune responseKappa-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
chemical synaptic transmissionKappa-type opioid receptorHomo sapiens (human)
sensory perceptionKappa-type opioid receptorHomo sapiens (human)
locomotory behaviorKappa-type opioid receptorHomo sapiens (human)
sensory perception of painKappa-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting opioid receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
response to insulinKappa-type opioid receptorHomo sapiens (human)
positive regulation of dopamine secretionKappa-type opioid receptorHomo sapiens (human)
negative regulation of luteinizing hormone secretionKappa-type opioid receptorHomo sapiens (human)
response to nicotineKappa-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
maternal behaviorKappa-type opioid receptorHomo sapiens (human)
eating behaviorKappa-type opioid receptorHomo sapiens (human)
response to estrogenKappa-type opioid receptorHomo sapiens (human)
estrous cycleKappa-type opioid receptorHomo sapiens (human)
response to ethanolKappa-type opioid receptorHomo sapiens (human)
regulation of saliva secretionKappa-type opioid receptorHomo sapiens (human)
behavioral response to cocaineKappa-type opioid receptorHomo sapiens (human)
sensory perception of temperature stimulusKappa-type opioid receptorHomo sapiens (human)
defense response to virusKappa-type opioid receptorHomo sapiens (human)
cellular response to lipopolysaccharideKappa-type opioid receptorHomo sapiens (human)
cellular response to glucose stimulusKappa-type opioid receptorHomo sapiens (human)
positive regulation of p38MAPK cascadeKappa-type opioid receptorHomo sapiens (human)
positive regulation of potassium ion transmembrane transportKappa-type opioid receptorHomo sapiens (human)
response to acrylamideKappa-type opioid receptorHomo sapiens (human)
positive regulation of eating behaviorKappa-type opioid receptorHomo sapiens (human)
conditioned place preferenceKappa-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayKappa-type opioid receptorHomo sapiens (human)
intracellular monoatomic ion homeostasisP2Y purinoceptor 2Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayP2Y purinoceptor 2Homo sapiens (human)
G protein-coupled purinergic nucleotide receptor signaling pathwayP2Y purinoceptor 2Homo sapiens (human)
positive regulation of mucus secretionP2Y purinoceptor 2Homo sapiens (human)
cellular response to ATPP2Y purinoceptor 2Homo sapiens (human)
blood vessel diameter maintenanceP2Y purinoceptor 2Homo sapiens (human)
G protein-coupled receptor signaling pathwayP2Y purinoceptor 2Homo sapiens (human)
monoatomic ion transportP2X purinoceptor 1Homo sapiens (human)
serotonin secretion by plateletP2X purinoceptor 1Homo sapiens (human)
regulation of vascular associated smooth muscle contractionP2X purinoceptor 1Homo sapiens (human)
apoptotic processP2X purinoceptor 1Homo sapiens (human)
signal transductionP2X purinoceptor 1Homo sapiens (human)
inseminationP2X purinoceptor 1Homo sapiens (human)
regulation of blood pressureP2X purinoceptor 1Homo sapiens (human)
neuronal action potentialP2X purinoceptor 1Homo sapiens (human)
calcium-mediated signalingP2X purinoceptor 1Homo sapiens (human)
platelet activationP2X purinoceptor 1Homo sapiens (human)
response to ATPP2X purinoceptor 1Homo sapiens (human)
synaptic transmission, glutamatergicP2X purinoceptor 1Homo sapiens (human)
purinergic nucleotide receptor signaling pathwayP2X purinoceptor 1Homo sapiens (human)
ceramide biosynthetic processP2X purinoceptor 1Homo sapiens (human)
excitatory postsynaptic potentialP2X purinoceptor 1Homo sapiens (human)
regulation of presynaptic cytosolic calcium ion concentrationP2X purinoceptor 1Homo sapiens (human)
positive regulation of calcium ion import across plasma membraneP2X purinoceptor 1Homo sapiens (human)
regulation of synaptic vesicle exocytosisP2X purinoceptor 1Homo sapiens (human)
calcium ion transmembrane transportP2X purinoceptor 1Homo sapiens (human)
response to hypoxiaP2X purinoceptor 3Homo sapiens (human)
signal transductionP2X purinoceptor 3Homo sapiens (human)
neuromuscular synaptic transmissionP2X purinoceptor 3Homo sapiens (human)
response to heatP2X purinoceptor 3Homo sapiens (human)
response to coldP2X purinoceptor 3Homo sapiens (human)
response to mechanical stimulusP2X purinoceptor 3Homo sapiens (human)
response to carbohydrateP2X purinoceptor 3Homo sapiens (human)
positive regulation of calcium ion transport into cytosolP2X purinoceptor 3Homo sapiens (human)
urinary bladder smooth muscle contractionP2X purinoceptor 3Homo sapiens (human)
peristalsisP2X purinoceptor 3Homo sapiens (human)
purinergic nucleotide receptor signaling pathwayP2X purinoceptor 3Homo sapiens (human)
regulation of synaptic plasticityP2X purinoceptor 3Homo sapiens (human)
behavioral response to painP2X purinoceptor 3Homo sapiens (human)
positive regulation of calcium-mediated signalingP2X purinoceptor 3Homo sapiens (human)
sensory perception of tasteP2X purinoceptor 3Homo sapiens (human)
establishment of localization in cellP2X purinoceptor 3Homo sapiens (human)
excitatory postsynaptic potentialP2X purinoceptor 3Homo sapiens (human)
protein homotrimerizationP2X purinoceptor 3Homo sapiens (human)
cellular response to ATPP2X purinoceptor 3Homo sapiens (human)
inorganic cation transmembrane transportP2X purinoceptor 3Homo sapiens (human)
calcium ion transmembrane transportP2X purinoceptor 3Homo sapiens (human)
defense responseP2Y purinoceptor 11Homo sapiens (human)
G protein-coupled receptor signaling pathwayP2Y purinoceptor 11Homo sapiens (human)
activation of adenylate cyclase activityP2Y purinoceptor 11Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayP2Y purinoceptor 11Homo sapiens (human)
calcium-mediated signalingP2Y purinoceptor 11Homo sapiens (human)
neuronal signal transductionP2Y purinoceptor 11Homo sapiens (human)
G protein-coupled purinergic nucleotide receptor signaling pathwayP2Y purinoceptor 11Homo sapiens (human)
cellular response to ATPP2Y purinoceptor 11Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (26)

Processvia Protein(s)Taxonomy
G-protein alpha-subunit bindingMu-type opioid receptorHomo sapiens (human)
G protein-coupled receptor activityMu-type opioid receptorHomo sapiens (human)
beta-endorphin receptor activityMu-type opioid receptorHomo sapiens (human)
voltage-gated calcium channel activityMu-type opioid receptorHomo sapiens (human)
protein bindingMu-type opioid receptorHomo sapiens (human)
morphine receptor activityMu-type opioid receptorHomo sapiens (human)
G-protein beta-subunit bindingMu-type opioid receptorHomo sapiens (human)
neuropeptide bindingMu-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor activityDelta-type opioid receptorHomo sapiens (human)
protein bindingDelta-type opioid receptorHomo sapiens (human)
receptor serine/threonine kinase bindingDelta-type opioid receptorHomo sapiens (human)
G protein-coupled enkephalin receptor activityDelta-type opioid receptorHomo sapiens (human)
neuropeptide bindingDelta-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor activityKappa-type opioid receptorHomo sapiens (human)
protein bindingKappa-type opioid receptorHomo sapiens (human)
receptor serine/threonine kinase bindingKappa-type opioid receptorHomo sapiens (human)
dynorphin receptor activityKappa-type opioid receptorHomo sapiens (human)
neuropeptide bindingKappa-type opioid receptorHomo sapiens (human)
protein bindingP2Y purinoceptor 2Homo sapiens (human)
signaling receptor activityP2Y purinoceptor 2Homo sapiens (human)
G protein-coupled purinergic nucleotide receptor activityP2Y purinoceptor 2Homo sapiens (human)
A1 adenosine receptor bindingP2Y purinoceptor 2Homo sapiens (human)
G protein-coupled UTP receptor activityP2Y purinoceptor 2Homo sapiens (human)
purinergic nucleotide receptor activityP2X purinoceptor 1Homo sapiens (human)
extracellularly ATP-gated monoatomic cation channel activityP2X purinoceptor 1Homo sapiens (human)
monoatomic cation channel activityP2X purinoceptor 1Homo sapiens (human)
protein bindingP2X purinoceptor 1Homo sapiens (human)
ATP bindingP2X purinoceptor 1Homo sapiens (human)
identical protein bindingP2X purinoceptor 1Homo sapiens (human)
suramin bindingP2X purinoceptor 1Homo sapiens (human)
protein-containing complex bindingP2X purinoceptor 1Homo sapiens (human)
ligand-gated calcium channel activityP2X purinoceptor 1Homo sapiens (human)
purinergic nucleotide receptor activityP2X purinoceptor 3Homo sapiens (human)
extracellularly ATP-gated monoatomic cation channel activityP2X purinoceptor 3Homo sapiens (human)
ATP bindingP2X purinoceptor 3Homo sapiens (human)
neurotransmitter receptor activityP2Y purinoceptor 11Homo sapiens (human)
signaling receptor activityP2Y purinoceptor 11Homo sapiens (human)
G protein-coupled ATP receptor activityP2Y purinoceptor 11Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (34)

Processvia Protein(s)Taxonomy
endosomeMu-type opioid receptorHomo sapiens (human)
endoplasmic reticulumMu-type opioid receptorHomo sapiens (human)
Golgi apparatusMu-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorHomo sapiens (human)
axonMu-type opioid receptorHomo sapiens (human)
dendriteMu-type opioid receptorHomo sapiens (human)
perikaryonMu-type opioid receptorHomo sapiens (human)
synapseMu-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorHomo sapiens (human)
neuron projectionMu-type opioid receptorHomo sapiens (human)
plasma membraneDelta-type opioid receptorHomo sapiens (human)
synaptic vesicle membraneDelta-type opioid receptorHomo sapiens (human)
dendrite membraneDelta-type opioid receptorHomo sapiens (human)
presynaptic membraneDelta-type opioid receptorHomo sapiens (human)
axon terminusDelta-type opioid receptorHomo sapiens (human)
spine apparatusDelta-type opioid receptorHomo sapiens (human)
postsynaptic density membraneDelta-type opioid receptorHomo sapiens (human)
neuronal dense core vesicleDelta-type opioid receptorHomo sapiens (human)
plasma membraneDelta-type opioid receptorHomo sapiens (human)
neuron projectionDelta-type opioid receptorHomo sapiens (human)
nucleoplasmKappa-type opioid receptorHomo sapiens (human)
mitochondrionKappa-type opioid receptorHomo sapiens (human)
cytosolKappa-type opioid receptorHomo sapiens (human)
plasma membraneKappa-type opioid receptorHomo sapiens (human)
membraneKappa-type opioid receptorHomo sapiens (human)
sarcoplasmic reticulumKappa-type opioid receptorHomo sapiens (human)
T-tubuleKappa-type opioid receptorHomo sapiens (human)
dendriteKappa-type opioid receptorHomo sapiens (human)
synaptic vesicle membraneKappa-type opioid receptorHomo sapiens (human)
presynaptic membraneKappa-type opioid receptorHomo sapiens (human)
perikaryonKappa-type opioid receptorHomo sapiens (human)
axon terminusKappa-type opioid receptorHomo sapiens (human)
postsynaptic membraneKappa-type opioid receptorHomo sapiens (human)
plasma membraneKappa-type opioid receptorHomo sapiens (human)
neuron projectionKappa-type opioid receptorHomo sapiens (human)
plasma membraneP2Y purinoceptor 2Homo sapiens (human)
plasma membraneP2Y purinoceptor 2Homo sapiens (human)
plasma membraneP2X purinoceptor 1Homo sapiens (human)
external side of plasma membraneP2X purinoceptor 1Homo sapiens (human)
secretory granule membraneP2X purinoceptor 1Homo sapiens (human)
specific granule membraneP2X purinoceptor 1Homo sapiens (human)
membrane raftP2X purinoceptor 1Homo sapiens (human)
postsynaptic membraneP2X purinoceptor 1Homo sapiens (human)
presynaptic active zone membraneP2X purinoceptor 1Homo sapiens (human)
glutamatergic synapseP2X purinoceptor 1Homo sapiens (human)
protein-containing complexP2X purinoceptor 1Homo sapiens (human)
plasma membraneP2X purinoceptor 1Homo sapiens (human)
plasma membraneP2X purinoceptor 3Homo sapiens (human)
axonP2X purinoceptor 3Homo sapiens (human)
Schaffer collateral - CA1 synapseP2X purinoceptor 3Homo sapiens (human)
hippocampal mossy fiber to CA3 synapseP2X purinoceptor 3Homo sapiens (human)
postsynapseP2X purinoceptor 3Homo sapiens (human)
receptor complexP2X purinoceptor 3Homo sapiens (human)
plasma membraneP2X purinoceptor 3Homo sapiens (human)
plasma membraneP2Y purinoceptor 11Homo sapiens (human)
plasma membraneP2Y purinoceptor 11Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (16)

Assay IDTitleYearJournalArticle
AID302984Agonist activity at P2Y11 receptor expressed in 1321N1 cells assessed as cytosolic calcium level2007Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23
New iantherans from the marine sponge Ianthella quadrangulata: novel agonists of the P2Y(11) receptor.
AID150144Antagonist activity against recombinant rat receptor P2X purinoceptor 2 (P2X2) at 10 uM, expressed in Xenopus oocytes2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Purine and pyrimidine (P2) receptors as drug targets.
AID150166Antagonist activity against recombinant rat P2X purinoceptor 4 (P2X4) at 30 uM, expressed in Xenopus oocytes2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Purine and pyrimidine (P2) receptors as drug targets.
AID150172Antagonist activity against recombinant rat P2X purinoceptor 6 (P2X6 )2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Purine and pyrimidine (P2) receptors as drug targets.
AID1372694Agonist activity at human N-terminal HA-tagged P2Y2 receptor expressed in 1321N1 cells2018Bioorganic & medicinal chemistry, 01-15, Volume: 26, Issue:2
Current knowledge on the nucleotide agonists for the P2Y2 receptor.
AID751193Antioxidant activity assessed as inhibiton of Fe2+-induced Fenton reaction-mediated hydroxyl radical formation from H2O2 relative to ATP2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
Highly efficient biocompatible neuroprotectants with dual activity as antioxidants and P2Y receptor agonists.
AID150495Antagonist activity against phospholipase C coupled rat P2Y purinoceptor 12 (P2Y12)2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Purine and pyrimidine (P2) receptors as drug targets.
AID150170Antagonist activity against recombinant rat P2X purinoceptor 5 (P2X5)2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Purine and pyrimidine (P2) receptors as drug targets.
AID152476Antagonist activity against recombinant human P2X purinoceptor 1 (P2X1 )2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Purine and pyrimidine (P2) receptors as drug targets.
AID150489Agonist activity against phospholipase C coupled human P2Y purinoceptor 11 (P2Y11)2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Purine and pyrimidine (P2) receptors as drug targets.
AID150470Evaluated for agonist activity against phospholipase C coupled P2Y purinoceptor 1 (P2Y1) of turkey erythrocytes2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Purine and pyrimidine (P2) receptors as drug targets.
AID150151Antagonist activity against recombinant human P2X purinoceptor 3 (P2X3 )2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Purine and pyrimidine (P2) receptors as drug targets.
AID150321Evaluated for agonist activity against phospholipase C coupled recombinant human P2Y purinoceptor 2 (P2Y2)2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Purine and pyrimidine (P2) receptors as drug targets.
AID751192Antioxidant activity assessed as inhibiton of Fe2+-induced Fenton reaction-mediated hydroxyl radical formation from H2O2 relative to trolox2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
Highly efficient biocompatible neuroprotectants with dual activity as antioxidants and P2Y receptor agonists.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2004Proceedings of the National Academy of Sciences of the United States of America, Nov-30, Volume: 101, Issue:48
Structural analysis of the inactive state of the Escherichia coli DNA polymerase clamp-loader complex.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2003Structure (London, England : 1993), Mar, Volume: 11, Issue:3
Nucleotide-induced conformational changes in an isolated Escherichia coli DNA polymerase III clamp loader subunit.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (962)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990146 (15.18)18.7374
1990's389 (40.44)18.2507
2000's289 (30.04)29.6817
2010's118 (12.27)24.3611
2020's20 (2.08)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 7.75

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index7.75 (24.57)
Research Supply Index6.88 (2.92)
Research Growth Index4.63 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (7.75)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews10 (1.03%)6.00%
Case Studies1 (0.10%)4.05%
Observational0 (0.00%)0.25%
Other964 (98.87%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]